Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Aug 19, 2019
Solid fundamentals helping propel Thermo Fisher Scientific higher

Solid fundamentals helping propel Thermo Fisher Scientific higher

Medical equipment provider Thermo Fisher Scientific (NYSE: TMO) has been trending higher for over two and a half years. Sure the stock pulled back in the fourth quarter of 2018, but even then it held up better than most stocks. One of the biggest reasons behind the rally has been good, consistent fundamentals.

Over the last three years the company has been able to grow earnings at a rate of 15% per year while sales have grown at a rate of 14% per year. In the most recent quarterly report, earnings increased by 11% while sales increased by 4%. Analysts expect the company to see earnings increase by 10% for 2019 as a whole while sales are expected to increase by 4.4%.

The company’s management efficiency measurements are above average as well with a return on equity of 17% and a profit margin of 21%.

The Tickeron Fundamental Analysis Overview shows a profit vs. risk rating of 9 for Thermo Fisher, indicating low risk on high returns. The average profit vs. risk rating for the industry is 75, placing this stock better than average.

The Tickeron Valuation Rating of 11 indicates that the company is seriously undervalued in the industry. A rating of 1 points to the most undervalued stocks, while a rating of 100 points to the most overvalued stocks. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization.

The daily chart shows that the stock has been trending higher since the end of December and there is a trend line connecting the lows from the last five months. The slope of the trend isn’t that high, but that seems to go along with the consistency of the fundamentals. The stock hasn’t rocketed higher and then fallen back, it has been on a consistent climb higher.

We see that the stock just recently hit the trend line again and that is the second time it has done so in August. The overbought/oversold indicators dropped in to oversold territory early in August and then reversed, but pulled back down again this past week. The daily stochastic readings made a bullish crossover on August 16 and that could be a good sign for the stock.

The stock also broke below its lower Bollinger band in early August and according to the Tickeron Technical Analysis Overview, in 22 of 31 cases where TMO's price broke its lower Bollinger Band, its price rose further in the following month. That puts the odds of a rally at 71% based on the past statistics.

Taking a look at the weekly chart we see that Thermo Fisher closed below its 52-week moving average for one week back in December and that is the only time the stock has done that in the last two and a half years.

The weekly stochastic readings have recently dipped below the 50 level for the first time since December and for only the seventh time in the last two and a half years. Almost all of the previous instances have marked good buying points for investors.

The sentiment toward Thermo Fisher is relatively bullish, but it seems to be warranted based on how well the company and stock have performed in recent years. There are 17 analysts following the stock at this time and 14 have it rated as a “buy”. There are also two “hold” ratings and one “sell” rating. This puts the overall buy percentage at 82.4% and that is above average.

The short interest ratio is at 1.9 currently and that is below average. This means that both analysts and short sellers are slightly more bullish toward Thermo Fisher than the average stock, but with the fundamental and technical picture, the bullish sentiment seems to be appropriate.

Related Ticker: TMO

Momentum Indicator for TMO turns positive, indicating new upward trend

TMO saw its Momentum Indicator move above the 0 level on June 25, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for TMO just turned positive on June 24, 2026. Looking at past instances where TMO's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

TMO moved above its 50-day moving average on June 24, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for TMO crossed bullishly above the 50-day moving average on June 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 267 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TMO broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.887) is normal, around the industry mean (13.099). P/E Ratio (29.862) is within average values for comparable stocks, (151.558). Projected Growth (PEG Ratio) (1.792) is also within normal values, averaging (1.656). TMO has a moderately low Dividend Yield (0.003) as compared to the industry average of (0.008). P/S Ratio (4.525) is also within normal values, averaging (7.708).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 17.48B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -1%. For the same Industry, the average monthly price growth was 13%, and the average quarterly price growth was 5%. CDNA experienced the highest price growth at 39%, while BNR experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -27% and the average quarterly volume growth was -16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 65
Price Growth Rating: 46
SMR Rating: 81
Profit Risk Rating: 91
Seasonality Score: 30 (-100 ... +100)
View a ticker or compare two or three
TMO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of analytical and environment monitoring instruments

Industry MedicalSpecialties

Profile
Details
Industry
Medical Specialties
Address
168 Third Avenue
Phone
+1 781 622-1000
Employees
122000
Web
https://www.thermofisher.com
Interact to see
Advertisement
TSM’s upcoming earnings carry outsized importance for the semiconductor industry. As the world’s leading contract chip manufacturer, TSMC underpins AI innovation for customers such as Nvidia and Apple. Its results often serve as a bellwether for global chip demand, capacity constraints, and pricing trends.
Goldman Sachs (GS) is expected to report Q4 2025 EPS of $11.65 on revenue of $13.85 billion, reflecting steady results as investment banking activity continues to recover.
Citigroup (C) is expected to report Q4 2025 EPS of $1.58, representing a 17.9% year-over-year increase, with revenue projected at $20.95 billion, up 7%. Bank of America (BAC) consensus estimates call for Q4 EPS of $0.96, up from $0.82, on revenue of $27.74 billion, reflecting 9.45% growth. JPMorgan Chase (JPM) is forecast to deliver Q4 EPS of $4.86, a modest 0.95% increase, with revenue expected to rise 8.13% to $46.25 billion.
Wells Fargo (WFC) is expected to report Q4 2025 earnings on January 14, 2026, with consensus calling for EPS of $1.66, up 16.9% year over year, and revenue of approximately $21.66 billion, a 6.3% increase. Investor focus will center on net interest income stabilization, growth in fee-based businesses such as investment banking and mortgages, and credit provisioning in a lower-rate environment.
Wall Street expects Infosys Q3 FY2026 EPS of $0.20, based on estimates from eight analysts, with revenue forecast at ₹452.37 billion (approximately $5.45 billion), compiled from 33 analysts.
BitMine Immersion Technologies (BMNR) is set to report Q1 FY2026 earnings on January 16, 2026, with consensus estimates calling for EPS of $0.15 and revenue of approximately $79.3 million.
Bank of America (BAC) and Wells Fargo (WFC) will both report Q4 2025 earnings on January 14, 2026, creating a rare same-day, apples-to-apples comparison.
Citigroup (C) is set to report Q4 2025 earnings on January 14, 2026, making it the immediate catalyst in this comparison. HSBC Holdings (HSBC) will release its Full-Year 2025 results on February 25, 2026, positioning it as a medium-term earnings event.
Wells Fargo’s quarterly results carry broader significance because the bank serves as a key indicator of U.S. consumer and commercial banking conditions. Its earnings often influence sentiment toward the entire large-cap banking sector. After a stretch of improved market conditions and stronger capital markets activity, investors are looking for confirmation that profit momentum is sustainable rather than driven by a single favorable quarter.
Infosys (INFY) will report Q3 FY2026 results on January 14, 2026, making it the immediate catalyst in this comparison. Accenture (ACN) last reported Q1 FY2026 earnings on December 18, 2025, with its next update scheduled later in the fiscal quarter.
BMNR reported fiscal Q4 and full-year FY2025 results (ending August 31, 2025), with profitability heavily influenced by digital-asset accounting and treasury positioning. Full-year diluted EPS: $13.39; Net income attributable to common stockholders: $328.161 million.
M&T Bank (MTB) is expected to deliver Q4 2025 EPS of $4.44–$4.46, representing roughly 13% year-over-year growth, driven by improving net interest income as funding costs decline. PNC Financial Services Group (PNC) is projected to post Q4 EPS of $4.19–$4.23, supported by about 1.5% sequential NII growth from rate relief and steady loan demand. U.S. Bancorp (USB) is forecast to earn $1.19 per share, an 11.2% annual increase, with revenues estimated at $7.33 billion, up 5%.
Dash (DASH.X) has ignited the crypto market with a powerful mid-January 2026 breakout, rallying more than 125% in a single week and decisively outperforming fellow privacy coins such as Monero and Zcash. The surge was fueled by a sharp short squeeze that wiped out nearly $4.9 million in bearish positions, alongside a major catalyst: Dash’s integration with Alchemy Pay, enabling direct fiat purchases across 173 countries.
As 2026 gets underway, ether.fi’s governance token (ETHFI.X) is emerging as a focal point for traders seeking exposure to Ethereum’s rapidly expanding liquid restaking ecosystem. With total value locked climbing to $7.8 billion, ether.fi now ranks as the second-largest staking protocol after Lido, underscoring its growing influence in the Ethereum economy.
The Schwab U.S. Small-Cap ETF (SCHA) is holding firm near the $28 level as 2026 begins, even as broader markets remain volatile. While short-term price action has been uneven, underlying signals suggest the ETF may be setting up for a meaningful breakout as interest-rate cuts revive small-cap equities. Technical models highlight an unusually favorable risk-reward profile—up to 22:1—with long-term momentum strengthening despite near-term consolidation.
The Vanguard Small-Cap Value ETF (VB) is quietly standing out in what has been a turbulent start to 2026. While many small-cap segments have struggled, VB has shown notable resilience, including a 3.2% jump on January 14, driven by renewed buying interest in undervalued industrial and financial stocks. This divergence from broader small-cap weakness suggests early signs of mean reversion, particularly as incoming economic data points toward eventual interest-rate relief.
The Vanguard Russell 2000 ETF (VTWO) has entered 2026 with renewed technical strength, breaking through several key indicators that suggest a potential trend reversal. On January 2, 2026, VTWO’s Momentum Indicator moved decisively above zero, a signal often associated with the early stages of bullish cycles. This followed an earlier technical milestone in December 2025, when the 10-day moving average crossed above the 50-day, drawing attention from momentum and swing traders alike.
CAOS, the trading ticker for IRIS Energy Limited, is emerging as a standout performer in early 2026 as two powerful trends converge: Bitcoin’s renewed surge and explosive demand for AI-ready data infrastructure. As Bitcoin pushes higher and investors hunt for leveraged exposure to both crypto and artificial intelligence, CAOS has attracted increasing attention from retail and quantitative traders alike.
In a surprising development that has caught the attention of both retail traders and institutional quantitative desks, Rubicon Technology Inc. (NASDAQ: RBC) has surfaced as one of early 2026’s more compelling AI-driven momentum candidates. After a relatively quiet close to 2025, the Illinois-based materials company—long associated with synthetic sapphire technology—has begun to display unexpected price strength, triggering alerts across algorithmic trading platforms.
In January 2026, Dell Technologies (DELL) experienced a sharp pullback, sliding nearly 9% as investor concerns mounted over escalating memory costs. Shortages and price increases in DRAM and NAND have squeezed margins across Dell’s server and PC businesses. The pressure was amplified after management acknowledged at CES 2026 that AI-focused PC marketing underperformed expectations and that component constraints were “unprecedented.”